3 US Penny Stocks With Market Caps Over $30M

As the U.S. markets experience fluctuations with major indices like the Dow Jones and Nasdaq reacting to earnings reports, investors are keenly observing economic indicators that could influence future interest rate decisions. In this context, penny stocks—typically smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer surprising value and potential for growth, especially when backed by strong financials, making them a noteworthy consideration for those seeking opportunities beyond the mainstream market names.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$93.03M	★★★★★★
BAB (OTCPK:BABB)	$0.8999	$6.54M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.40	$9.63M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.56	$1.91B	★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.3052	$11.04M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.57	$50.16M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.78	$43.03M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.14	$20.75M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9143	$81.09M	★★★★★☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Cumberland Pharmaceuticals (NasdaqGS:CPIX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally, with a market cap of $37.49 million.

Operations: The company's revenue is primarily generated from its specialty pharmaceutical products, totaling $36.79 million.

Market Cap: $37.49M

Cumberland Pharmaceuticals, with a market cap of US$37.49 million, remains unprofitable but has reduced losses over the past five years. The company holds more cash than its total debt and maintains a cash runway exceeding three years if current free cash flow trends persist. Recent FDA approval for a streamlined dosing regimen of Acetadote® enhances its product portfolio, potentially improving patient outcomes. However, increased debt-to-equity ratio and heightened share price volatility pose challenges. Despite these issues, Cumberland's seasoned management and board provide stability as they navigate the competitive pharmaceutical landscape.

• Dive into the specifics of Cumberland Pharmaceuticals here with our thorough balance sheet health report.
• Explore historical data to track Cumberland Pharmaceuticals' performance over time in our past results report.

Forge Global Holdings (NYSE:FRGE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Forge Global Holdings, Inc. operates a financial services platform in California with a market cap of approximately $145.76 million.

Operations: The company's revenue is primarily derived from its Integrated Private Markets Service Provider segment, which generated $79.80 million.

Market Cap: $145.76M

Forge Global Holdings, with a market cap of US$145.76 million, faces challenges as it seeks to regain compliance with NYSE's minimum share price rule. The company has experienced significant insider selling and shareholder dilution over the past year. Despite being unprofitable, Forge reports revenue growth in its Integrated Private Markets Service Provider segment, totaling US$79.80 million annually. It benefits from a debt-free status and sufficient short-term assets to cover liabilities, offering some financial stability amid volatility concerns. The recent appointment of James Nevin as CFO brings extensive capital markets experience to support strategic initiatives during this transitional period.

• Jump into the full analysis health report here for a deeper understanding of Forge Global Holdings.
• Gain insights into Forge Global Holdings' future direction by reviewing our growth report.

CreateAl Holdings (OTCPK:TSPH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: CreateAl Holdings Inc. is an artificial intelligence technology company specializing in video game and anime production and publishing, with a market cap of $93.05 million.

Operations: The company's revenue is derived entirely from its Transportation - Trucking segment, amounting to $0.31 million.

Market Cap: $93.05M

CreateAI Holdings, formerly TuSimple Holdings, is navigating a complex landscape with a market cap of US$93.05 million and pre-revenue status, generating just US$0.31 million from its Transportation - Trucking segment. The company is debt-free but faces high volatility and an unprofitable position with negative return on equity. Recent events include board restructuring efforts and shareholder activism challenging management decisions, notably rejecting a US$0.46 per share acquisition offer deemed undervalued by the board. The management team has limited tenure experience, which may affect strategic direction amid ongoing financial challenges and investor scrutiny.

• Click here and access our complete financial health analysis report to understand the dynamics of CreateAl Holdings.
• Gain insights into CreateAl Holdings' past trends and performance with our report on the company's historical track record.

Next Steps

• Discover the full array of 713 US Penny Stocks right here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com